Contineum Therapeutics has announced the initiation of patient dosing in its Phase 1b clinical trial of PIPE-791, an LPA1 receptor antagonist, for the treatment of relapsing-remitting multiple sclerosis (RRMS). This marks a significant step in the development of a novel therapeutic approach for MS, a chronic autoimmune disease affecting the central nervous system.
The Phase 1b trial is designed to evaluate the safety, tolerability, and pharmacokinetics of PIPE-791 in patients diagnosed with RRMS. The study aims to gather crucial data that will inform dose selection for future, larger clinical trials. Topline data from the Phase 1b trial is anticipated in the second half of 2025.
Rationale for LPA1 Receptor Antagonism in MS
Multiple sclerosis is characterized by inflammation and demyelination in the brain and spinal cord, leading to a range of neurological symptoms. The LPA1 receptor is implicated in neuroinflammation and fibrosis, making it a potential therapeutic target for MS. By blocking the LPA1 receptor, PIPE-791 aims to reduce inflammation and potentially slow the progression of the disease.
Current Treatment Landscape and Unmet Needs
While there are several approved therapies for RRMS, many patients still experience disease progression and significant disability. Current treatments often come with side effects, highlighting the need for new therapeutic options with improved safety and efficacy profiles. PIPE-791 represents a novel mechanism of action that could address some of the unmet needs in MS treatment.
Trial Design and Objectives
The Phase 1b trial is a randomized, double-blind, placebo-controlled study. The primary objectives are to assess the safety and tolerability of PIPE-791 in RRMS patients. Secondary endpoints include evaluating the pharmacokinetics of the drug and exploring potential biomarkers of efficacy. The trial will enroll patients meeting specific inclusion criteria, ensuring a well-defined study population.
Future Directions
Contineum Therapeutics is also developing PIPE-307 for depression, in collaboration with Johnson & Johnson, and for RRMS. The company's pipeline reflects a commitment to addressing significant unmet needs in neurological and psychiatric disorders. The progress of PIPE-791 and PIPE-307 will be closely watched by the medical community and patients alike.
